Company intelligence / Profile preview

FugenBio

Ownership: Private
Development stage: Commercial

Overview

FugenBio has developed CLEPS®, a proprietary biogenic cosmetic ingredient shown to improve skin elasticity, hydration, and brightness. Human trials initially focused on blood sugar improvement also revealed significant benefits for skin health. The company’s products have achieved strong commercial success with millions of units sold globally[5].

Therapeutic areas: Metabolic DisordersDermatology
Modalities: Bioactive compoundsBiogenic ingredients (notably CLEPS®)
Industry: Non-Drug Biotech

Drug pipeline

1 asset

Cepona

Commercial

Indications: Type 2 diabetes, Insulin resistance

Beyond the preview

Go deeper on FugenBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FugenBio.

Explore the full profile